On 12 Nov 2026 Danaher Corporation closed at $232.16, +2.0% this year; market cap $164.09bn, P/E 37.9.
Health Care · Life Sciences Tools & Services · NYSE · United States
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
| Market cap | $164.09bn |
| P/E (trailing) | 37.9 |
| EPS (TTM) | $6.13 |
| Beta | 0.80 |
| Dividend | $1.60 |
| Dividend yield | 0.69% |
| Ex-dividend date | 30 Sep 2026 |
| Latest report | 21 Oct 2026 |
| Next earnings | 20 Jan 2027 |
| YTD | +2.0% |
| 1Y | +6.6% |
| 3Y | +6.4% |
| 5Y | -2.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $24.57bn | $3.61bn | $5.26bn |
| 2024 | $23.88bn | $3.90bn | $5.30bn |
| 2023 | $23.89bn | $4.74bn | $5.78bn |
| 2022 | $26.64bn | $7.21bn | $7.37bn |
| 2021 | $29.45bn | $6.43bn | $7.06bn |
We publish no single base value for Danaher Corporation. Our valuation methods put it between $146.16 and $169.24 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.